French drugmaker Sanofi SA is weighing a purchase of U.S.-based Insmed Inc., Bloomberg reported, citing people with knowledge of the matter.

A deal of this size would rank among the industry’s largest deals in recent years. Insmed, with a market value exceeding $26 billion, focuses on developing and marketing therapies for rare medical conditions affecting small patient populations. Its stock price has dropped roughly 40% during the past year.
During trading on the Nasdaq Thursday, the company’s stock price rose sharply by 17%.
Sources indicate that Sanofi is exploring a possible purchase of Insmed alongside its advisers.
Still, no assurance exists that an agreement will ultimately be achieved. Additionally, other prospective buyers of the company may appear.
source: bloomberg.com